GGrantIndex
← Leaderboards

Scott M. Grundy

University Of Texas Sw Med Ctr/Dallas

$3,966,518
Attributed
$3,966,518
Total exposure
12
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $115.4K · FY200507
$200K$150K$100K$50K$0
'05
'06
'07

Funding mix

By agency

NIH$3,966,518 · 12

By mechanism

M01$3,516,518 · 11
K07$450,000 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectNutrition Related TagBlood Lipoprotein MetabolismHuman Therapy EvaluationLow Density LipoproteinHigh Density LipoproteinsCholesterolObesityAdipose TissueInsulin Sensitivity /ResistanceBlood Disorder ChemotherapyAndrogensCaucasian AmericanAtherosclerosisAfrican AmericanCardiovascular Disorder PreventionCurriculumCardiovascular Disorder ChemotherapyAntihyperlipoproteinemic AgentDietary LipidDiet TherapyDisease /Disorder Proneness /RiskDosage

Grant awards (25)

EZETIMIBE OR STATIN MONOTHERAPY VS CO-ADMINISTRATION IN ETHNIC GROUPS$34,271
M01 · FY2007 · RR · contact PI
EZETIMIBE OR STATIN MONOTHERAPY VS CO-ADMINISTRATION IN ETHNIC GROUPS$92,397
M01 · FY2006 · RR · contact PI
COMPARISON OF TRIGLYCERIDES ON PLASMA LEVELS OF BETAHYDROXYBUTERANE$16,236
M01 · FY2006 · RR · contact PI
EFFECT OF N-3 FATTY ACIDS ON LIVER FAT CONTENT$6,790
M01 · FY2006 · RR · contact PI
EFFECT OF N-3 FATTY ACIDS ON LIVER FAT CONTENT$54,852
M01 · FY2005 · RR
EZETIMIBE OR STATIN MONOTHERAPY VS CO-ADMINISTRATION IN ETHNIC GROUPS$12,740
M01 · FY2005 · RR
Effect of n-3 fatty acids on liver fat content$85,492
M01 · FY2004 · RR
GLUCOSE METABOLISM IN OBESE/NONOBESE NONINSULIN DEPENDENT DIABETES PATIENTS$321,374
M01 · FY2002 · RR
GENETIC POLYMORPHISMS OF HEPATIC LIPASE$321,374
M01 · FY2002 · RR
EFFECT OF LIFIBROL ON PLASMA LIPOPROTEINS$321,374
M01 · FY2002 · RR
METABOLIC BASIS OF RACIAL DIFFERENCES IN HDL LEVELS$321,374
M01 · FY2002 · RR
CAUSES AND MANAGEMENT OF PRIMARY HYPERCHOLESTEROLEMIA$321,374
M01 · FY2002 · RR
CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION$150,000
K07 · FY2002 · HL
GENETIC POLYMORPHISMS OF HEPATIC LIPASE$321,374
M01 · FY2001 · RR
EFFECT OF LIFIBROL ON PLASMA LIPOPROTEINS$321,374
M01 · FY2001 · RR
METABOLIC BASIS OF RACIAL DIFFERENCES IN HDL LEVELS$321,374
M01 · FY2001 · RR
GLUCOSE METABOLISM IN OBESE/NONOBESE NONINSULIN DEPENDENT DIABETES PATIENTS$321,374
M01 · FY2001 · RR
CAUSES AND MANAGEMENT OF PRIMARY HYPERCHOLESTEROLEMIA$321,374
M01 · FY2001 · RR
CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION$150,000
K07 · FY2001 · HL
CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION$150,000
K07 · FY2000 · HL
GENETIC POLYMORPHISMS OF HEPATIC LIPASE$0
M01 · FY2000 · RR
EFFECT OF LIFIBROL ON PLASMA LIPOPROTEINS$0
M01 · FY2000 · RR
METABOLIC BASIS OF RACIAL DIFFERENCES IN HDL LEVELS$0
M01 · FY2000 · RR
GLUCOSE METABOLISM IN OBESE/NONOBESE NIDDM PTS$0
M01 · FY2000 · RR
CAUSES AND MANAGEMENT OF PRIMARY HYPERCHOLESTEROLEMIA$0
M01 · FY2000 · RR